{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.75","upperLimit":"28.0","value":"10.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"}],"units":"Participants"}],"description":"Tmax is the time to reach maximum (peak) peripheral blood after single dose administration (days). Actual sampling times were taken into consideration for the calculation of cellular kinetic parameters.","dispersionType":"Full Range","groups":[{"description":"All participants who were enrolled in the study","id":"OG000","title":"CTL019"}],"paramType":"MEDIAN","populationDescription":"Participants in the Cellular kinetic set (CKAS) with an available value for the outcome measure. The CKAS consisted of patients in the Efficacy analysis set who provided an evaluable cellular kinetic profile (at least 1 cellular kinetic parameter).","reportingStatus":"POSTED","timeFrame":"up to 60 months after infusion","title":"Tmax; Cellular Kinetic Parameter of Tisagenlecleucel Transgene Levels by qPCR, Based on Clinical Response by IRC Assessment","type":"SECONDARY","unitOfMeasure":"days"}